Brussels - Delayed Quote EUR

UCB SA (UCB.BR)

124.55 +0.80 (+0.65%)
At close: April 26 at 5:35 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for UCB.BR

Recent News: UCB.BR

View More
UCB SA's Dividend Analysis

UCB SA's Dividend Analysis
GuruFocus.com 2 days ago
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
PR Newswire 15 days ago
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
PR Newswire 17 days ago
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
PR Newswire 23 days ago
UCB Convening Notice to the General Meeting of the Shareholders 2024

UCB Convening Notice to the General Meeting of the Shareholders 2024
GlobeNewswire last month
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
PR Newswire last month
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
PR Newswire last month
UCB on Growth Path for a Decade Plus

UCB on Growth Path for a Decade Plus
PR Newswire last month
20 Most Valuable Belgian Companies in 2024

20 Most Valuable Belgian Companies in 2024
Insider Monkey 2 months ago
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
PR Newswire 3 months ago
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
PR Newswire 4 months ago
UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
PR Newswire 4 months ago
View More

Related Tickers

TUB.BR Financière de Tubize SA
94.60
+1.83%
 
ARGX.BR argenx SE
349.30
+0.90%
 
ONWD.BR Onward Medical N.V.
4.6900
+1.08%
 
GLPG Galapagos NV
28.76
+0.45%
 
ARGX argenx SE
372.80
+1.14%
 
MRUS Merus N.V.
45.04
+0.24%
 
GLPG.AS Galapagos NV
26.68
+0.45%
 
ATXS Astria Therapeutics, Inc.
9.00
-1.85%
 
RVMD Revolution Medicines, Inc.
35.96
+1.78%
 
ELVN Enliven Therapeutics, Inc.
17.18
+2.38%